Evonile Pharma Limited (formerly Novartis India Limited) announced its unaudited financial results for the quarter and half year ended September 30, 2026, pursuant to Regulation 30 of SEBI Listing Regulations. This represents the company's first results after a change of control.

Financial Performance

  • Q2 FY27 Revenue from Operations: ₹56.1 crore
  • Q2 FY27 Operating EBITDA (Earnings before Interest, Depreciation and Taxes): -₹31.8 crore
  • H1 FY27 Revenue from Operations: ₹159.9 crore
  • H1 FY27 Profit after Tax: -₹45.3 crore

The negative EBITDA and PAT are attributed to one-time transition costs and upfront investment in organizational build-out. Results are not comparable with the previous year due to the change in control and business model.

Corporate Developments

ChrysCapital, one of India's leading private equity investors, acquired a controlling 70.68% stake in the company, bringing the pharmaceutical business under dedicated private equity ownership. The company has transitioned from a single-customer business model to marketing its brands with its own distribution network, field force, and operating systems within two months of the change in control.

Strategic Portfolio Expansion

The company completed two strategic transactions during the quarter:

1. Acquisition of Minipress XL (cardiology therapy area)

2. Ophthalmology in-licensing agreement (retina portfolio)

These expansions add cardiology and ophthalmology to the company's therapeutic areas, creating new platforms for sustainable growth.

Flagship Brands and Market Position

The company's flagship brands include Voveran, Methergin, Calcium-Sandoz, Tegrital, and Myfortic, which hold #1 positions in their covered markets across pain management, gynaecology, wellness, neuroscience, and transplant.

Business Model and Outlook

The company operates an asset-light model and markets its portfolio through its own therapy-aligned field force and distribution network. For H2 FY27, priorities include completing the organizational build-out, establishing an appropriate cost structure, and building a strong team to lead the next phase of growth.